HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pieter A van Doorn Selected Research

Intravenous Immunoglobulins (IVIG)

1/2022Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
1/2022Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.
1/2022Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
11/2021European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
10/2021Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
1/2021Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
1/2021European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
1/2021Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
1/2020Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
1/2019Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pieter A van Doorn Research Topics

Disease

44Guillain-Barre Syndrome
01/2022 - 04/2003
26Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
01/2022 - 06/2005
25Glycogen Storage Disease Type II (Pompe's Disease)
12/2022 - 06/2003
12Polyneuropathies (Polyneuropathy)
01/2022 - 12/2005
7Pain (Aches)
11/2021 - 10/2007
7Disease Progression
02/2017 - 03/2002
7Infections
08/2014 - 04/2005
5Autoimmune Diseases (Autoimmune Disease)
12/2015 - 06/2010
4Muscle Weakness
01/2021 - 03/2002
4Respiratory Insufficiency (Respiratory Failure)
02/2017 - 06/2010
4Inflammation (Inflammations)
02/2017 - 02/2010
4Hypertension (High Blood Pressure)
01/2017 - 02/2010
4Muscular Diseases (Myopathy)
10/2015 - 06/2003
3Neuralgia (Stump Neuralgia)
11/2021 - 01/2018
3Sudden Infant Death (SID)
01/2021 - 06/2013
3Fatigue
12/2014 - 03/2011
3Miller Fisher Syndrome (Fisher Syndrome)
06/2013 - 10/2008
3Diarrhea
03/2011 - 02/2008
2COVID-19
06/2022 - 05/2022
2Peripheral Nervous System Diseases (PNS Diseases)
01/2018 - 03/2014
2Diabetes Mellitus
01/2016 - 06/2007
2Neuromuscular Diseases (Neuromuscular Disease)
12/2015 - 06/2010
2Monoclonal Gammopathy of Undetermined Significance
12/2015 - 09/2015
1AIDS-Related Complex (ARC)
06/2022
1Breakthrough Infections
06/2022
1Demyelinating Diseases (Demyelinating Disease)
01/2022
1Epstein-Barr Virus Infections
01/2021
1Multiple Sclerosis
01/2021
1Multiple Myeloma
01/2018
1Painful Neuropathy
01/2018
1Hyperalgesia
12/2017
1Hypoalbuminemia
02/2017
1Venous Thrombosis (Deep-Vein Thrombosis)
01/2017
1Sepsis (Septicemia)
01/2017
1Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2016

Drug/Important Bio-Agent (IBA)

35Intravenous Immunoglobulins (IVIG)FDA Link
01/2022 - 06/2005
14AntibodiesIBA
06/2022 - 04/2003
11Immunoglobulin G (IgG)IBA
01/2022 - 05/2005
11Adrenal Cortex Hormones (Corticosteroids)IBA
11/2021 - 05/2009
11GangliosidesIBA
01/2016 - 04/2003
7Immunoglobulins (Immunoglobulin)IBA
11/2021 - 11/2010
6Immunosuppressive Agents (Immunosuppressants)IBA
06/2022 - 11/2010
6AcidsIBA
11/2013 - 08/2005
5Biomarkers (Surrogate Marker)IBA
01/2021 - 06/2011
5Methotrexate (Mexate)FDA LinkGeneric
01/2017 - 03/2002
4alpha-Glucosidases (Acid Maltase)IBA
01/2022 - 06/2003
4human GAA protein (Myozyme)FDA Link
01/2022 - 12/2010
4Amantadine (Aman)FDA LinkGeneric
01/2021 - 03/2011
4Mycophenolic Acid (Cellcept)FDA LinkGeneric
01/2017 - 05/2009
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2017 - 05/2009
4Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2017 - 05/2009
4Rituximab (Mabthera)FDA Link
01/2017 - 05/2009
4Azathioprine (Imuran)FDA LinkGeneric
01/2017 - 05/2009
4GlycogenIBA
10/2015 - 08/2007
4GlucosidasesIBA
11/2013 - 12/2010
3AntigensIBA
06/2022 - 04/2003
3Immunomodulating AgentsIBA
01/2017 - 11/2010
3InterferonsIBA
01/2017 - 05/2009
3Glucose (Dextrose)FDA LinkGeneric
12/2016 - 06/2007
3Insulin (Novolin)FDA Link
10/2016 - 02/2010
3Immunoglobulin M (IgM)IBA
12/2015 - 12/2005
3CaprylatesIBA
02/2012 - 02/2008
2EnzymesIBA
01/2022 - 08/2007
2MethylprednisoloneFDA LinkGeneric
01/2022 - 10/2007
2Pharmaceutical PreparationsIBA
11/2021 - 01/2021
2Proteins (Proteins, Gene)FDA Link
01/2021 - 05/2009
2Biological ProductsIBA
01/2017 - 08/2016
2Interferon beta-1aFDA Link
01/2017 - 06/2013
2Creatine Kinase (Creatine Phosphokinase)IBA
02/2016 - 03/2002
2Interferon-betaIBA
06/2013 - 11/2010
2Interferon-alpha (Interferon Alfa)IBA
06/2013 - 11/2010
2Indicators and Reagents (Reagents)IBA
03/2011 - 06/2010
2IceIBA
09/2010 - 02/2008
2OligosaccharidesIBA
07/2010 - 02/2008
1Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1Natalizumab (Tysabri)FDA Link
01/2021
1N 30IBA
01/2020
1Alemtuzumab (Campath)FDA Link
01/2020
1SaltsIBA
12/2019
1PanzygaIBA
01/2018
1Bortezomib (Velcade)FDA Link
01/2018
1Purinergic P2X3 ReceptorsIBA
12/2017
1Serum AlbuminIBA
02/2017
1AlbuminsIBA
02/2017
1LipidsIBA
01/2017

Therapy/Procedure

18Enzyme Replacement Therapy
12/2022 - 06/2003
10Plasma Exchange
11/2021 - 06/2005
9Therapeutics
01/2022 - 06/2005
5Artificial Respiration (Mechanical Ventilation)
02/2017 - 06/2010
3Immunotherapy
01/2021 - 02/2004
3Aftercare (After-Treatment)
02/2017 - 03/2014
3Mechanical Ventilators (Ventilator)
05/2015 - 08/2011
2Enzyme Therapy
11/2019 - 09/2012
2Activities of Daily Living (ADL)
07/2017 - 03/2015
1Drug Tapering
01/2018
1Ligation
12/2017
1Tracheostomy
01/2017
1Central Venous Catheters
01/2017
1Catheters
01/2017